Hangzhou Tigermed Consulting Co. Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and to… Read more
Hangzhou Tigermed Consulting Co. Ltd (HNGZY) - Net Assets
Latest net assets as of September 2025: $24.71 Billion USD
Based on the latest financial reports, Hangzhou Tigermed Consulting Co. Ltd (HNGZY) has net assets worth $24.71 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.79 Billion) and total liabilities ($4.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.71 Billion |
| % of Total Assets | 85.84% |
| Annual Growth Rate | 52.18% |
| 5-Year Change | 34.75% |
| 10-Year Change | 2157.64% |
| Growth Volatility | 99.4 |
Hangzhou Tigermed Consulting Co. Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Hangzhou Tigermed Consulting Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hangzhou Tigermed Consulting Co. Ltd (2009–2024)
The table below shows the annual net assets of Hangzhou Tigermed Consulting Co. Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $24.06 Billion | -1.59% |
| 2023-12-31 | $24.45 Billion | +7.82% |
| 2022-12-31 | $22.68 Billion | +10.07% |
| 2021-12-31 | $20.61 Billion | +15.38% |
| 2020-12-31 | $17.86 Billion | +223.43% |
| 2019-12-31 | $5.52 Billion | +81.98% |
| 2018-12-31 | $3.03 Billion | +7.63% |
| 2017-12-31 | $2.82 Billion | +53.22% |
| 2016-12-31 | $1.84 Billion | +72.60% |
| 2015-12-31 | $1.07 Billion | +16.25% |
| 2014-12-31 | $916.90 Million | +21.42% |
| 2013-12-31 | $755.14 Million | +8.76% |
| 2012-12-31 | $694.32 Million | +375.48% |
| 2011-12-31 | $146.03 Million | +52.45% |
| 2010-12-31 | $95.79 Million | +116.43% |
| 2009-12-31 | $44.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Tigermed Consulting Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 365892.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.69 Billion | 42.03% |
| Common Stock | $864.95 Million | 4.18% |
| Other Components | $11.12 Billion | 53.78% |
| Total Equity | $20.67 Billion | 100.00% |
Hangzhou Tigermed Consulting Co. Ltd Competitors by Market Cap
The table below lists competitors of Hangzhou Tigermed Consulting Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Provident Financial Services Inc
NYSE:PFS
|
$2.55 Billion |
|
MAINFREIGHT LTD
F:NK7
|
$2.55 Billion |
|
NIPPON YUSEN K.K.SP.DR1/5
F:NYK
|
$2.55 Billion |
|
Wanxiang Qianchao Co Ltd
SHE:000559
|
$2.55 Billion |
|
ENN Ecological Holdings Co Ltd
SHG:600803
|
$2.55 Billion |
|
Tomra Systems ASA
PINK:TMRAF
|
$2.55 Billion |
|
China Nuclear Engineering Co
SHG:601611
|
$2.54 Billion |
|
Haemonetics Corporation
NYSE:HAE
|
$2.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Tigermed Consulting Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,026,774,725 to 20,670,653,449, a change of -356,121,276 (-1.7%).
- Net income of 405,143,491 contributed positively to equity growth.
- Dividend payments of 642,156,083 reduced retained earnings.
- Share repurchases of 270,889,712 reduced equity.
- Other comprehensive income decreased equity by 113,027,344.
- Other factors increased equity by 264,808,372.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $405.14 Million | +1.96% |
| Dividends Paid | $642.16 Million | -3.11% |
| Share Repurchases | $270.89 Million | -1.31% |
| Other Comprehensive Income | $-113.03 Million | -0.55% |
| Other Changes | $264.81 Million | +1.28% |
| Total Change | $- | -1.69% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Tigermed Consulting Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 38.42x to 0.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $0.10 | $4.00 | x |
| 2010-12-31 | $0.20 | $4.00 | x |
| 2011-12-31 | $0.29 | $4.00 | x |
| 2012-12-31 | $1.29 | $4.00 | x |
| 2013-12-31 | $1.16 | $4.00 | x |
| 2014-12-31 | $1.33 | $4.00 | x |
| 2015-12-31 | $1.54 | $4.00 | x |
| 2016-12-31 | $2.31 | $4.00 | x |
| 2017-12-31 | $3.39 | $4.00 | x |
| 2018-12-31 | $3.56 | $4.00 | x |
| 2019-12-31 | $5.67 | $4.00 | x |
| 2020-12-31 | $20.17 | $4.00 | x |
| 2021-12-31 | $20.81 | $4.00 | x |
| 2022-12-31 | $22.64 | $4.00 | x |
| 2023-12-31 | $24.31 | $4.00 | x |
| 2024-12-31 | $23.98 | $4.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Tigermed Consulting Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.14%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.39x
- Recent ROE (1.96%) is below the historical average (15.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 18.41% | 12.42% | 0.93x | 1.59x | $3.56 Million |
| 2010 | 33.96% | 25.81% | 1.02x | 1.28x | $22.37 Million |
| 2011 | 33.86% | 24.73% | 1.03x | 1.32x | $33.68 Million |
| 2012 | 9.82% | 26.64% | 0.35x | 1.06x | $-1.26 Million |
| 2013 | 12.64% | 27.95% | 0.42x | 1.09x | $19.66 Million |
| 2014 | 14.53% | 20.09% | 0.46x | 1.57x | $39.14 Million |
| 2015 | 15.59% | 16.33% | 0.59x | 1.61x | $56.04 Million |
| 2016 | 8.65% | 11.98% | 0.49x | 1.47x | $-22.03 Million |
| 2017 | 12.02% | 17.84% | 0.47x | 1.43x | $50.66 Million |
| 2018 | 17.69% | 20.52% | 0.54x | 1.60x | $205.33 Million |
| 2019 | 19.92% | 30.02% | 0.37x | 1.78x | $419.09 Million |
| 2020 | 10.86% | 54.81% | 0.16x | 1.21x | $137.92 Million |
| 2021 | 15.86% | 55.13% | 0.22x | 1.31x | $1.06 Billion |
| 2022 | 10.25% | 28.32% | 0.26x | 1.40x | $48.25 Million |
| 2023 | 9.63% | 27.42% | 0.25x | 1.41x | $-77.83 Million |
| 2024 | 1.96% | 6.14% | 0.23x | 1.39x | $-1.66 Billion |
Industry Comparison
This section compares Hangzhou Tigermed Consulting Co. Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Tigermed Consulting Co. Ltd (HNGZY) | $24.71 Billion | 18.41% | 0.17x | $2.55 Billion |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |